CIP2A is a target of bortezomib in human triple negative breast cancer cells

INTRODUCTION: Triple negative breast cancer (TNBC) is very aggressive and currently has no specific therapeutic targets, such as hormone receptors or human epidermal growth factor receptor type 2 (HER2); therefore, prognosis is poor. Bortezomib, a proteasome inhibitor, may exert efficacy in TNBC thr...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Tseng, Ling-Ming, Liu, Chun-Yu, Chang, Kung-Chi, Chu, Pei-Yi, Shiau, Chung-Wai, Chen , Kuen-Feng
Format: Artigo
Jezik:Inglês
Izdano: BioMed Central 2012
Teme:
Research Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3446403/
https://ncbi.nlm.nih.gov/pubmed/22537901
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/bcr3175
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items